Aliases & Classifications for Leiomyoma

MalaCards integrated aliases for Leiomyoma:

Name: Leiomyoma 12 74 54 43 15
Leiomyomatous Neoplasm 12
Leiomyomatous Tumor 12
Uterine Fibroids 71
Fibroid Tumor 71
Leiomyomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:127
MeSH 43 D007889
NCIt 49 C3157
SNOMED-CT 67 702978006
UMLS 71 C0023267 C0042133

Summaries for Leiomyoma

Disease Ontology : 12 A cell type benign neoplasm that is a benign tumor of smooth muscle cells.

MalaCards based summary : Leiomyoma, also known as leiomyomatous neoplasm, is related to bizarre leiomyoma and cellular leiomyoma, and has symptoms including pelvic pain An important gene associated with Leiomyoma is HMGA2 (High Mobility Group AT-Hook 2), and among its related pathways/superpathways are Gastric cancer and Pathways in cancer. The drugs Anastrozole and Dienogest have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and breast, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and cellular

Wikipedia : 74 A leiomyoma, also known as fibroids, is a benign smooth muscle tumor that very rarely becomes cancer... more...

Related Diseases for Leiomyoma

Diseases related to Leiomyoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 871)
# Related Disease Score Top Affiliating Genes
1 bizarre leiomyoma 34.7 PGR MED12 FH ESR1 ACTC1
2 cellular leiomyoma 34.6 MED12 DES
3 lung leiomyoma 34.5 PGR ESR1
4 leiomyoma cutis 34.4 MED12 FH
5 leiomyoma, uterine 34.3 TGFB3 RAD51B PGR MED12 HMGA2 GNRH1
6 breast leiomyoma 34.2 PGR FH CD34
7 orbital leiomyoma 34.2 S100A1 GNRH1
8 vulvar leiomyoma 34.1 PGR HMGA2 ESR1 CD34
9 benign metastasizing leiomyoma 34.0 VIM PGR DES CYP19A1 ACTC1
10 deep leiomyoma 33.8 KIT CD34
11 hereditary leiomyomatosis and renal cell cancer 33.7 PTCH1 FH
12 gastric leiomyoma 33.7 KIT FH
13 gallbladder leiomyoma 33.6 KIT CD34
14 small intestine leiomyoma 33.4 PTCH1 KIT CD34
15 liver leiomyoma 33.4 PGR KIT ESR1 CD34
16 subserous uterine fibroid 33.4 PGR CYP19A1
17 endobronchial leiomyoma 33.1 KIT CD34
18 leiomyomatosis 32.2 PGR MED12 KIT GNRH1 FH ESR1
19 leiomyosarcoma 32.0 VIM S100A1 PGR MED12 KIT HMGA2
20 myofibroma 31.9 S100A1 DES CD34
21 gastrointestinal stromal tumor 31.8 VIM S100A1 KIT DES CD34 ACTC1
22 intravenous leiomyomatosis 31.6 PGR MED12 HMGA2 ESR1 DES CD34
23 adenomyosis 31.5 PGR GNRH1 ESR2 ESR1 CYP19A1
24 endometriosis 31.4 PGR GNRH1 ESR2 ESR1 CYP19A1
25 diffuse peritoneal leiomyomatosis 31.3 PGR MED12 GNRH1
26 infertility 31.3 PGR GNRH1 ESR2 CYP19A1
27 spindle cell sarcoma 31.2 VIM DES CD34 ACTC1
28 ovarian cyst 31.2 GNRH1 ESR2 CYP19A1
29 lymphangioleiomyomatosis 31.2 PGR GNRH1 ESR1 DES
30 pleomorphic lipoma 31.1 PGR HMGA2 CD34
31 prostatic hypertrophy 31.1 PGR ESR1 CYP19A1
32 vaginal discharge 31.1 PGR GNRH1 ESR1 CYP19A1
33 rare tumor 31.1 KIT DES ACTC1
34 endometrial hyperplasia 31.0 PGR ESR2 ESR1 CYP19A1
35 fibroma 30.9 VIM S100A1 PTCH1 DES CD34 ACTC1
36 fibromatosis 30.9 VIM DES ACTC1
37 mesenchymal cell neoplasm 30.9 KIT HMGA2 CD34
38 in situ carcinoma 30.8 PGR ESR1 CYP19A1
39 pneumothorax 30.8 VIM PGR GNRH1 ACTC1
40 granular cell tumor 30.8 VIM S100A1 DES
41 myxoid leiomyosarcoma 30.8 PGR ACTC1
42 liposarcoma 30.7 VIM HMGA2 DES CD34
43 adenomyoma 30.7 PGR MED12 GNRH1 ESR1
44 malignant mesenchymoma 30.7 DES CD34
45 endometrial adenocarcinoma 30.6 VIM PGR ESR2 ESR1
46 meningioma, familial 30.6 PTCH1 PGR ESR1 CD34
47 pleomorphic adenoma 30.6 VIM S100A1 HMGA2 DES ACTC1
48 myoma 30.6 PGR MED12 KIT HMGA2 GNRH1 FH
49 leydig cell tumor 30.6 GNRH1 ESR1 CYP19A1
50 pelvic organ prolapse 30.6 PGR ESR2 ESR1

Graphical network of the top 20 diseases related to Leiomyoma:



Diseases related to Leiomyoma

Symptoms & Phenotypes for Leiomyoma

UMLS symptoms related to Leiomyoma:


pelvic pain

GenomeRNAi Phenotypes related to Leiomyoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 ESR1 ESR2 FH RAD51B

MGI Mouse Phenotypes related to Leiomyoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.28 ACTC1 CD34 CYP19A1 DES ESR1 ESR2
2 homeostasis/metabolism MP:0005376 10.25 ACTC1 CD34 CYP19A1 DES ESR1 ESR2
3 cardiovascular system MP:0005385 10.23 ACTC1 CYP19A1 DES ESR1 ESR2 KIT
4 integument MP:0010771 10.02 CD34 CYP19A1 DPT ESR1 ESR2 GNRH1
5 muscle MP:0005369 9.96 ACTC1 CYP19A1 DES ESR1 ESR2 KIT
6 limbs/digits/tail MP:0005371 9.87 ESR1 ESR2 KIT MED12 PGR PTCH1
7 normal MP:0002873 9.73 ACTC1 COL4A6 CYP19A1 ESR1 ESR2 GNRH1
8 neoplasm MP:0002006 9.7 CD34 ESR1 ESR2 GNRH1 KIT PGR
9 skeleton MP:0005390 9.28 CYP19A1 ESR1 ESR2 GNRH1 KIT MED12

Drugs & Therapeutics for Leiomyoma

Drugs for Leiomyoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
2
Dienogest Approved Phase 4 65928-58-7
3
Desogestrel Approved Phase 4 54024-22-5 40973
4
Ferrous fumarate Approved Phase 4 141-01-5
5
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
6
leucovorin Approved Phase 4 58-05-9 6006 143
7
Zinc Approved, Investigational Phase 4 7440-66-6 32051
8
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
9
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
10
Zinc oxide Approved Phase 4 1314-13-2
11
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
12
Calcium carbonate Approved, Investigational Phase 4 471-34-1
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Ibuprofen Approved Phase 4 15687-27-1 3672
15
Dinoprostone Approved Phase 4 363-24-6 5280360
16
Goserelin Approved Phase 4 65807-02-5 5311128 47725
17
Remifentanil Approved Phase 4 132875-61-7 60815
18
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
19
Prilocaine Approved Phase 4 721-50-6 4906
20
Morphine Approved, Investigational Phase 4 57-27-2 5288826
21
Misoprostol Approved Phase 4 59122-46-2 5282381
22
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
23
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
24
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
25
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
26
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
27
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
28
Polyestradiol phosphate Approved Phase 4 28014-46-2
29
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
30
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
31
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
32
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
33
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
34
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
35
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
36
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
37
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
38
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
39
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
41
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
42
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
43
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
44
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
45
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
46
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
47
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
48
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
49
Cobalamin Experimental Phase 4 13408-78-1 6857388
50
Fibrinolysin Investigational Phase 4 9004-09-5

Interventional clinical trials:

(show top 50) (show all 417)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
2 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
3 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Unknown status NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
4 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
5 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
6 The Effect of UPA on Women Ovarian Reserve Unknown status NCT02361892 Phase 4 ulipristal acetate
7 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
8 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
9 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
10 Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena, a Randomized Clinical Trial Unknown status NCT03186586 Phase 4 Ulipristal acetate;Placebo
11 Ulipristal Versus Gonadotropin-releasing Hormone Agonists Prior to Laparoscopic Myomectomy: a Double Blind Randomized Controlled Trial Unknown status NCT02288130 Phase 4 GnRHa;Ulipristal
12 Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids Completed NCT00159328 Phase 4
13 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
14 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
15 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
16 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
17 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
18 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
19 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
20 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
21 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
22 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
23 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy: A Randomized Controlled Study Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
24 Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy Completed NCT03308643 Phase 4 Oxytocin
25 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
26 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
27 Deep Sedation in Spontaneously Breathing Patients Combined With Local Anesthesia Versus General Anesthesia in Gynecological Patients at Same Day Surgical at Hospitalsenheden Horsens Completed NCT01412632 Phase 4 Remifentanil, propofol and citanest
28 Safety and Efficacy of Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy; A Randomized Controlled Trial Completed NCT03892668 Phase 4 Tranexamic Acid;oxytocin;placebo
29 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
30 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
31 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
32 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
33 Bioenergetic and Metabolic Consequences of the Loss of Ovarian Function in Women - 2018 Recruiting NCT04043520 Phase 4 GnRH antagonist;Estrogen Product;Placebo estradiol;Placebo GnRH antagonist
34 Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
35 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
36 Use of Oxytocin in MRI-HIFU Treatment Enrolling by invitation NCT03937401 Phase 4 Oxytocin
37 The Effect of Estrogen in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis Enrolling by invitation NCT03620929 Phase 4 Estradiol Valerate
38 Effect of Transversus Abdominal Plane Block Using Liposomal Bupivacaine Versus Standard Bupivacaine for Open Myomectomy: A Prospective Randomized Control Trial Not yet recruiting NCT04272086 Phase 4 Bupivacaine;Bupivacaine liposome;normal saline
39 Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions Not yet recruiting NCT04364581 Phase 4 Letrozole;Placebo
40 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
41 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
42 Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population Terminated NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
43 The Effectiveness and Safety of Ulipristal Acetate in Women With Symptomatic Uterine Fibroid Terminated NCT04132349 Phase 4 Ulipristal Acetate 5 mg
44 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
45 Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized Terminated NCT01776203 Phase 4 Medroxyprogesterone 17-Acetate
46 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
47 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
48 A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids Unknown status NCT02189083 Phase 3 TSD
49 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
50 Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial. Unknown status NCT03509168 Phase 2, Phase 3 Misoprostol Pfizer Brand

Search NIH Clinical Center for Leiomyoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Leuprolide
Leuprolide Acetate

Cochrane evidence based reviews: leiomyoma

Genetic Tests for Leiomyoma

Anatomical Context for Leiomyoma

MalaCards organs/tissues related to Leiomyoma:

40
Uterus, Smooth Muscle, Breast, Small Intestine, Lung, Prostate, Ovary

Publications for Leiomyoma

Articles related to Leiomyoma:

(show top 50) (show all 11887)
# Title Authors PMID Year
1
Progesterone is essential for maintenance and growth of uterine leiomyoma. 54 61
20375184 2010
2
Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. 61 54
20414849 2010
3
Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. 54 61
19464003 2010
4
Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. 54 61
20414841 2010
5
microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. 54 61
19906824 2010
6
Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. 54 61
19328471 2010
7
Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. 54 61
19741209 2010
8
Mayer-Rokitansky-Kustner Hauser syndrome complicated by either uterine leiomyoma or ovarian tumor. 61 54
20178550 2010
9
Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. 54 61
20124487 2010
10
Association of N-terminal pro B-type natriuretic peptide and sex hormone-binding globulin in non-obese peri- and postmenopausal women. 61 54
19945451 2010
11
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. 61 54
19135657 2010
12
Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. 54 61
19700613 2009
13
Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors. 54 61
19851199 2009
14
Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. 54 61
19808856 2009
15
A leiomyoma presenting as an exophytic periurethral mass: a case report and review of the literature. 54 61
19573833 2009
16
Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. 54 61
19179429 2009
17
High aromatase expression in uterine leiomyoma tissues of African-American women. 54 61
19240151 2009
18
Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. 54 61
19176543 2009
19
Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. 54 61
19151755 2009
20
A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole. 54 61
18523791 2009
21
Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. 54 61
18980243 2009
22
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. 54 61
18249392 2009
23
Genistein suppresses spontaneous oviduct tumorigenesis in quail. 54 61
20155619 2009
24
Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. 61 54
18853184 2008
25
Single nucleotide polymorphisms in the progesterone receptor gene and association with uterine leiomyoma tumor characteristics and disease risk. 61 54
18691687 2008
26
Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. 61 54
18166184 2008
27
Treatment of symptomatic uterine leiomyoma with letrozole. 54 61
18854113 2008
28
The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. 54 61
19012097 2008
29
Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. 54 61
18701604 2008
30
[Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. 61 54
18565690 2008
31
Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience. 54 61
18710984 2008
32
[Fibroblast growth factor gene expression in uterine leiomyomas]. 61 54
18819464 2008
33
Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. 54 61
18580309 2008
34
Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2). 61 54
18164802 2008
35
CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. 54 61
18448745 2008
36
Differential metabolic consequences of fumarate hydratase and respiratory chain defects. 61 54
18313410 2008
37
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. 61 54
18403645 2008
38
Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. 61 54
18281245 2008
39
[Expression of CD117, CD34, SMA, S-100 protein, Vim and desmin in patients with gastrointestinal stromal tumors]. 61 54
18359707 2008
40
Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. 54 61
18216291 2008
41
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. 61 54
18182446 2008
42
Expression of sex hormone-binding globulin, oxytocin receptor, caveolin-1 and p21 in leiomyoma. 54 61
17952758 2008
43
A limited immunocytochemical panel for the distinction of subepithelial gastrointestinal mesenchymal neoplasms sampled by endoscopic ultrasound-guided fine-needle aspiration. 61 54
18208801 2008
44
Chemoprevention of fibroid tumors by [-]-epigallocatechin-3-gallate in quail. 54 61
19083394 2008
45
Expression of mRNA for chemokines and chemokine receptors in tissues of the myometrium and uterine leiomyoma. 54 61
19024011 2008
46
Association study between catechol-O-methyltransferase polymorphisms and uterine leiomyomas in a Japanese population. 61 54
18390078 2008
47
Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. 61 54
18089606 2007
48
"Seedling" mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. 54 61
18059218 2007
49
Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower genital tract. 54 61
17654722 2007
50
A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. 54 61
16973256 2007

Variations for Leiomyoma

Expression for Leiomyoma

Search GEO for disease gene expression data for Leiomyoma.

Pathways for Leiomyoma

GO Terms for Leiomyoma

Biological processes related to Leiomyoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.83 VIM KIT HMGA2 CD34 ACTC1
2 positive regulation of transcription, DNA-templated GO:0045893 9.73 TGFB3 PTCH1 MED12 HMGA2 ESR2 ESR1
3 transcription initiation from RNA polymerase II promoter GO:0006367 9.62 PGR MED12 ESR2 ESR1
4 positive regulation of phospholipase C activity GO:0010863 9.46 KIT ESR1
5 embryonic neurocranium morphogenesis GO:0048702 9.4 TGFB3 MED12
6 paracrine signaling GO:0038001 9.37 PGR CD34
7 muscle filament sliding GO:0030049 9.33 VIM DES ACTC1
8 stem cell differentiation GO:0048863 9.13 KIT HMGA2 ESR1
9 mammary gland development GO:0030879 8.92 TGFB3 PTCH1 PGR CYP19A1

Molecular functions related to Leiomyoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.98 VIM TGFB3 S100A1 PGR ESR2 ESR1
2 ATPase binding GO:0051117 9.58 S100A1 PGR ESR1
3 steroid hormone receptor activity GO:0003707 9.54 PGR ESR2 ESR1
4 repressing transcription factor binding GO:0070491 9.5 PGR ESR2 ESR1
5 nuclear receptor activity GO:0004879 9.33 PGR ESR2 ESR1
6 estrogen receptor activity GO:0030284 9.26 ESR2 ESR1
7 estrogen response element binding GO:0034056 8.96 ESR2 ESR1
8 steroid binding GO:0005496 8.8 PGR ESR2 ESR1

Sources for Leiomyoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....